Cost-effectiveness of long-term intrathecal morphine therapy for pain associated with failed back surgery syndrome
References (28)
- et al.(1994)
- et al.
An overview of the incidences and costs of low back pain
Orthop Clin North Am
(1991) National Center for Health Statistics
(1990)- et al.
Cost analysis of two implantable narcotic delivery systems
J Pain Symptom Manage
(1991) - et al.
Avoiding bias in the conduct of and reporting of cost-effectiveness research sponsored by pharmaceutical companies
NEJM
(1991) - et al.
Intraspinal drug therapy
Nurs Clin North Am
(1991) Intrathecal infusional therapies for intractable pain: Patient management guidelines
J Pain Symptom Manage
(1993)- et al.
Intrathecal infusional analgesia for nonmalignant pain: Analgesic efficacy of intrathecal opioid with or without bupivacaine
J Pain Symptom Manage
(1993) - et al.
Altered sexual function and decreased testosterone in patients receiving intraspinal opioids
J Pain Symptom Manage
(1994)
Constant infusion of morphine for intractable cancer pain using an implanted pump
J Neurosurg
Neurological Division. Returned Product Analysis
Cited by (110)
The Development of Algorithms for Pain Care Including Neuromodulation Therapies: Introducing the SAFE Principles
2018, Neuromodulation: Comprehensive Textbook of Principles, Technologies, and Therapies, Second Edition: Volume 1-3Intrathecal administration of nociceptin/orphanin FQ receptor agonists in rats: A strategy to relieve chemotherapy-induced neuropathic hypersensitivity
2015, European Journal of PharmacologyCitation Excerpt :Previous study, conducted to evaluate the efficacy of intrathecal and intraperitoneal injections of morphine on neuropathic pain induced by T13 spinal hemisection in rats, demonstrated that higher dose of systemic morphine is needed to produce the same anti-allodynic effect reached with the i.t. injection (Kim et al., 2003). The i.t. route offers a safe and effective alternative when i.v. or oral opioids are only partially effective (Grady and Raphael, 2008) e.g. for the management of chronic non-cancer pain (Biggs et al., 2011; De Lissovoy et al., 1997; Hassenbusch et al., 1997). Recent studies support the long-term effectiveness following 3 years of treatment (Duarte et al., 2012).
Acute and subchronic antinociceptive effects of nociceptin/orphanin FQ receptor agonists infused by intrathecal route in rats
2015, European Journal of PharmacologyLongevity and cost of implantable intrathecal drug delivery systems for chronic pain management: A retrospective analysis of 365 patients
2015, NeuromodulationCitation Excerpt :While they are currently in widespread use, the real-world cost of implanting and maintaining functioning intrathecal drug delivery systems has not been quantified, especially in a long-term cohort. De Lissovoy et al. quantified the costs of implanting and maintaining an intrathecal drug delivery system in a modeled population where adverse event rates were drawn from published data supplemented by experts’ estimates of complication rates (1997) (2). The cumulative cost incurred by one real-world cohort of patients in Saskatchewan was found to total 29,410 Canadian dollars when assessed over a 5-year period (7).
Interventional therapies for chronic low back pain
2014, NeuromodulationCitation Excerpt :Contraindications to pump implant include common surgical contraindications such as infection and anticoagulation. The most frequent indication for intrathecal delivery of opioids for noncancer chronic pain is FBSS (127,131–134). Intrathecal infusion with implantable pumps has been used successfully in treatment of back pain due to osteoporosis and vertebral compression fractures (135,136).
Intrathecal pain pumps: Indications, patient selection, techniques, and outcomes
2014, Neurosurgery Clinics of North America